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ABSTRACT 
 
APOE ε4, the most significant genetic risk factor for Alzheimer disease (AD), may mask effects 
of other loci. We re-analyzed genome-wide association study (GWAS) data from the 
International Genomics of Alzheimer’s Project (IGAP) Consortium in APOE ε4+ (10,352 cases 
and 9,207 controls) and APOE ε4- (7,184 cases and 26,968 controls) subgroups as well as in the 
total sample testing for interaction between a SNP and APOE ε4 status. Suggestive associations 
(P<1x10
-4
) in stage 1 were evaluated in an independent sample (stage 2) containing 4,203 
subjects (APOE ε4+: 1,250 cases and 536 controls; APOE ε4-: 718 cases and 1,699 controls). 
Among APOE ε4- subjects, novel genome-wide significant (GWS) association was observed 
with 17 SNPs (all between KANSL1 and LRRC37A on chromosome 17 near MAPT) in a meta-
analysis of the stage 1 and stage 2 datasets (best SNP, rs2732703, P=5·8x10
-9
). Conditional 
analysis revealed that rs2732703 accounted for association signals in the entire 100 kilobase 
region that includes MAPT. Except for previously identified AD loci showing stronger 
association in APOE ε4+ subjects (CR1 and CLU) or APOE ε4- subjects (MS4A6A/MS4A4A/ 
MS4A6E), no other SNPs were significantly associated with AD in a specific APOE genotype 
subgroup. In addition, the finding in the stage 1 sample that AD risk is significantly influenced 
by the interaction of APOE with rs1595014 in TMEM106B (P=1·6x10
-7
) is noteworthy because 
TMEM106B variants have previously been associated with risk of frontotemporal dementia. 
Expression quantitative trait locus analysis revealed that rs113986870, one of the GWS SNPs 
near rs2732703, is significantly associated with four KANSL1 probes that target transcription of 
the first translated exon and an untranslated exon in hippocampus (P<1.3x10
-8
), frontal cortex 
(P<1.3x10
-9
), and temporal cortex (P<1.2x10
-11
). Rs113986870 is also strongly associated with a 
MAPT probe that targets transcription of alternatively spliced exon 3 in frontal cortex (P=9.2x10
-
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6
) and temporal cortex (P=2.6x10
-6
). Our APOE-stratified GWAS is the first to show GWS 
association for AD with SNPs in the chromosome 17q21.31 region. Replication of this finding in 
independent samples is needed to verify that SNPs in this region have significantly stronger 
effects on AD risk in persons lacking APOE ε4 compared to persons carrying this allele, and if 
this is found to hold, further examination of this region and studies aimed at deciphering the 
mechanism(s) are warranted. 
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INTRODUCTION 
The common late-onset form of Alzheimer disease (AD) has a strong genetic component,
1
 a 
portion of which is explained by APOE and several other genes identified by positional mapping, 
targeted gene analysis and genome-wide association studies (GWAS).
2-4
 Together, these loci 
account for less than one-half of the heritable component in AD susceptibility, of which 20%-
25% is due to APOE.
4,5
 Because many of the known AD loci cluster in biological pathways, 
including those involved in inflammation, lipid metabolism and processing, and intracellular 
trafficking of Aβ, there are likely more AD risk loci that are difficult to detect because of very 
weak effect size, allelic heterogeneity, or rare variants. To examine yet another hypothesis, 
namely, that associations for some loci may be obscured by confounding or interaction with 
other loci, we conducted a two-stage GWAS in APOE genotype subgroups using the large 
resources of the International Genomics of Alzheimer’s Project (IGAP). 
 
METHODS 
Study Population 
Details of the stage 1 sample from the International Genomics of Alzheimer’s Project (IGAP) 
Consortium including subject recruitment, genotyping, imputation, quality control, population 
substructure, and statistical methods for association analyses were previously described.
4
 In 
brief, phenotype and genotype data, including APOE genotypes, for a total of 53,711 subjects 
were assembled by IGAP from the Alzheimer’s Disease Genetic Consortium (ADGC), the 
Cohorts for Heart and Ageing Research in Genomic Epidemiology (CHARGE) consortium, the 
European Alzheimer's Disease Initiative (EADI), and the Genetic and Environmental Risk in 
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Alzheimer’s Disease (GERAD) consortium.  Characteristics of this sample are in 
Supplementary Table S1. 
The stage 2 dataset included GWAS and APOE genotype data for 4,203 subjects of European 
ancestry from the ADC4, ADC5, ADC6, MTV, Pfizer, and TARCC datasets in the ADGC. 
These individuals were recruited under protocols approved by the appropriate Institutional 
Review Boards. Details of the individual datasets are provided in the Supplementary Materials 
and summarized in Supplementary Table S1.  
 
Procedures 
QC, Imputation, and Population Substructure in Stage 2 Datasets    
Quality control of the clinical and genotype data in these cohorts was performed using 
procedures described elsewhere.
4
 SNP genotypes in each stage 2 dataset were imputed with 
IMPUTE2 using reference haplotypes from the March 2012 release of 1000 Genomes. We 
compared imputation results for selected variants in the stage 1 datasets using the March 2012 
release of 1000 Genomes and prior imputation on the December 2010 release, and found no 
significant difference in the distribution of genotype probabilities between old and new 
imputations for the same samples among the original ADGC datasets. We used actual APOE 
genotypes when available because previously we observed that imputation in this region using 
the 1000 Genomes reference panel is unreliable.
5
 Population substructure was evaluated within 
each dataset by principal components (PC) analysis using EIGENSTRAT 
(http://www.hsph.harvard.edu/alkes-price/software/) and a subset of 21,109 SNPs common to all 
genotyping platforms.  
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Statistical Analysis 
Genome-wide Association Study: Within each stage 1 dataset, genome-wide association 
analyses were conducted separately in subgroups of subjects with and without the APOE ε4 
allele using a logistic generalized linear model (GLM) in case-control datasets and a logistic 
generalized estimating equation (GEE) in family-based datasets. The potential independent effect 
of the APOE ε2 allele was not examined because of the paucity of carriers of this allele, thus 
rendering very small cell sizes particularly among AD cases and in smaller datasets. Cox-
proportional hazards models were used to evaluate association with incident AD in three 
CHARGE cohorts. A quantitative estimate between 0 and 2 for the dose of the reference allele 
for a SNP was used to incorporate the uncertainty of the imputation estimates. Interaction 
between a SNP and APOE genotype was evaluated in the APOE genotype subgroups combined 
within each dataset using regression models including age, sex, the first three PCs, and terms for 
the SNP, APOE ε4 status, and interaction between the SNP and APOE ε4 status. Results for each 
model across datasets were combined by meta-analysis using the inverse variance method 
implemented in the software package METAL (http://www.sph.umich.edu/csg/abecasis/Metal/). 
Effect sizes were weighted by their inverse variance and a combined estimate was calculated by 
summing the weighted estimates and dividing by the summed weights. SNPs with a minor allele 
frequency >5% that were available in at least 50% of the datasets were included in the meta-
analysis. The meta-analysis P-value for association was estimated by the summarized test 
statistic, after applying genomic control within each individual study.  
Follow-up Analysis in Stage 2 Datasets: SNPs attaining a P-value <10
-4
 in the stage 1 GWAS 
were evaluated in each of the stage 2 GWAS datasets, containing a total of 1,786 APOE ε4+ and 
2,417 APOE ε4- subjects (Supplementary Table S1), using the same approach described above.  
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Gene Expression Analysis 
The effect of top-ranked SNPs on gene expression was evaluated using an open access database 
of control brain microarray data (BRAINEAC) made publically available by the UK Human 
Brain Expression Consortium (http://caprica.genetics.kcl.ac.uk/BRAINEAC). This dataset 
contains information generated by analysis of tissue samples obtained from 12 different central 
nervous system regions in 134 individuals. Details of the expression quantitative trait locus 
(eQTL) analysis are reported elsewhere.
6
 In this study, the experiment-wise significance 
threshold for association of a genetic marker with expression was determined to be 1.6x10
-7
 at 
the gene level and 1.8x10
-6
 for individual exons. Potential for functionality of the top-ranked 
SNPs was assessed using the Regulome database (http://www.regulomedb.org). 
 
RESULTS 
We conducted a genome-wide association study for AD using datasets stratified by APOE 
genotype assembled by IGAP which were from the ADGC, CHARGE consortium, EADI, and 
GERAD consortium. Meta-analyses were performed separately in APOE ε4+ (10,246 cases and 
11,924 controls) and APOE ε4- (7,231 cases and 19,603 controls) subgroups, as well as the total 
sample using a model including a term for the interaction of the SNP with the APOE ε4 status. 
There was limited genomic inflation in the GWAS results in the APOE ε4+ (λ=1.05) and APOE 
ε4- (λ=1.06) groups, but not in the total sample (λ=0.98) testing the ε4 * SNP interaction 
(Supplementary Figure S1). Genome-wide significant (GWS) association (P<5x10
-8
) for AD 
was found in five distinct regions (CR1, BIN1, CLU, PICALM and APOE) in the APOE ε4+ 
subgroup (Supplementary Figure S2A, Supplementary Table S2) and four distinct regions 
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(BIN1, HBEGF, MS4A6A/MS4A4A, SLC24A4, and APOE) in the APOE ε4- subgroup 
(Supplementary Figure S2B, Supplementary Table S2). No significant SNP*APOE 
interactions were found in the total group (Supplementary Figure S2C). Suggestive association 
(P<10
-6
) was observed with SNPs in five novel loci in the APOE ε4- subgroup (SOX14/CLDN18, 
ACSL6, FAM20C, MAPT region, and CDR2L; Supplementary Figure S2B, Supplementary 
Table S3) and with 21 TMEM106B SNPs (top result: rs1595014, P=1.6x10
-7
) (Supplementary 
Figure S2C, Supplementary Table S3).  
Approximately 1,130 SNPs from 38 regions (including seven previously established AD loci) 
were tested in Stage 2 (Supplementary Table S3). Follow-up analyses of the novel loci 
confirmed association with SNPs in CDC42SE2-ACSL6, KANSL1/LRRC37A, and CDR2L in the 
stage 2 sample (Table 1, Supplementary Table S2), but only SNPs near MAPT and between 
KANSL1 and LRRC37A (Figure 1A) were genome-wide significant after combining results from 
the stage 1 and stage 2 samples (best SNP: rs2732703, meta-analysis: P=5.8x10
-9
).  The 
association was consistent in nearly all datasets which contained rs2732703 information (Figure 
1B). To verify the reliability of the association with rs2732703, an imputed SNP, we compared 
rs2732703 allele dosages obtained directly by genotyping using a Taqman assay with those 
derived from imputation among 1,010 subjects from the ACT, ADC4, ADC5 and ADC6 
datasets. The correlation of these values, 0.813 in the entire sample and 0.834 among APOE ε4- 
subjects, as well as a genotype misclassification rate of only 3.5% among subjects with imputed 
probability scores > 0.8 for a particular genotype, suggest that our association findings were not 
influenced substantially by imputation quality. 
Further examination of this region in the total sample revealed an association peak spanning 
more than 1.25 Mb that contains 15 genes (Figure 1A). Within this region, 17 SNPs were GWS, 
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have MAFs ranging from 0.13 to 0.17, and are located in a 10.2 kb segment upstream of both 
KANSL1 and LRRC37A (Supplementary Table S4). Nominally significant association was 
observed with only one of these SNPs among ε4+ subjects (rs2732703, P=0.02) 
(Supplementary Table S3). Although the odds ratios (OR) for effect of the effect of minor 
allele on AD risk were substantially lower for all of the GWS SNPs in the ε4- group (0.54< OR 
<0.86) than in the ε4+ group (0.76< β <1.04), there was no evidence of interaction with APOE 
genotype (Supplementary Table S3). The minor alleles of these SNPs reduced AD risk by 
20%-37% in the ε4- group. The 350 kb gap in the broad association signal is punctuated at one 
end by a “cliff” adjacent to the MAPT-KANSL1-LRRC37A association peak (Figure 1). This gap 
is populated by relatively few SNPs and contains several copy number variation (CNV) 
polymorphisms.
7,8
 To explore the possibility that the association observed in the present analysis 
is explained by previously identified haplotypes H1/H2 in the MAPT region,
8
 we evaluated six 
models in the entire dataset conditioning on rs8070723 (an H1/H2 tagging SNP), rs2732703, or 
rs199533. Rs2732703 remained significant in models conditioning on rs8070723 (P=0.013) or 
rs199533 (P=0.0020), and rs8070723 was marginally significant in the model conditioning on 
rs199533 (P=0.043) (Supplementary Table S5, Supplementary Figure S3). These results 
suggest that KANSL1/LRRC37A is the only AD risk locus in this region. 
We also examined the effect of APOE ɛ4 status on previously established AD loci 
(Supplementary Table S2). Four of these loci attained genome-wide significance in at least one 
of the APOE subgroups (Table 2), and the association signal in the MS4A cluster region was 
evident primarily in the APOE ε4- subgroup (Supplementary Figure S4). The association of 
AD with CR1, BIN1, and CLU was supported in both APOE subgroups.   
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Next, we interrogated the BRAINEAC database to determine whether any of the 17 GWS SNPs 
located between KANSL1 and LRRC37A are cis-eQTLs. Data were available for only one of 
these SNPs (rs113986870) which is in high LD with and 2,461 base pairs away from rs2732703 
(r
2
 and D’>0.9). Ten exon probes from four genes (KANSL1, LRRC37A4P, MAPT, and 
C17orf69) were significantly associated with rs113986870 when averaged across all brain 
regions (Table 3). Rs113986870 was significantly associated with gene-level expression (Figure 
2A) as well as with exon-level expression (Figure 2B) in hippocampus, temporal cortex, and 
cerebellum. In these brain regions, rs113986870 was significantly associated with KANSL1 
probes 3762011, 3762012 and 3762013 that measure expression of the first translated exon. 
Additionally, we observed that expression of probe 3760518 (Supplementary Figure S5A) 
present in all three transcripts (NM_001193466, NM_015443, and NM_001193465) and 
3760219 in transcript variant 2 (NM_015443) was significantly associated with rs113986870 
(Supplementary Figure S5B), while expression of probe 3760217 in transcript variant 1 
((NM_001193466) was not significant (Supplementary Figure S5C), indicating that alternative 
splicing may be a crucial mechanism for regulating KANSL1 expression. Rs113986870 was also 
strongly associated with MAPT transcription (Supplementary Figure S6A) and in particular 
with probe 3723712 that targets transcription of alternatively spliced exon 3 in frontal cortex 
(P<9.2x10
-6
) and temporal cortex (P<2.6x10
-6
) (Supplementary Figure S6B). The rs113986870 
minor allele (A), which is associated with reduced risk of AD (Supplementary Table S4), 
increased expression of the target exons in KANSL1 and MAPT (Figure 2, Supplementary 
Figure S6, Supplementary Figure S7). The association with LRRC37A4P exon probe 3759898 
was significant in all three AD-related brain regions (P<3.6x10
-9
). The association of 
rs113986870 with exon probe 3723594 for C17orf69 was significant in hippocampus only 
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(P=1.6x10
-7
). Five of the GWS SNPs including rs2732703 and rs113986870 are located within a 
transcription factor binding site or a DNase sensitivity peak and two of these five SNPs, 
including rs2668626 which is only 47 bp from rs2732703, have also been identified within an 
eQTL (Supplementary Table S4). 
 
DISCUSSION 
This study was undertaken to identify loci whose effect on AD risk may be obscured by 
confounding or interaction with APOE genotype. Our APOE-stratified GWAS is the first to show 
GWS association for AD with SNPs in the chromosome 17q21.31 region including MAPT, 
KANSL1 and LRRC37A. Among the genes expected to emerge from GWAS but never seen 
before is MAPT which encodes the microtubule-associated protein tau (MAPT) found in AD 
neurofibrillary tangles. The association peak is located between KANSL1 and LRRC37A, 
approximately 200 kb downstream of MAPT, in a subset of subjects that do not possess the 
APOE ε4 allele. Although the association signal includes MAPT, conditional analysis suggests 
that the causal variant(s) are more likely located in a DNA segment between the 5’ end of 
KANSL1 and 5’ end of LRRC37A and not within MAPT or another gene distal to LRRC37A.  
The nature of the AD-related functional variant could not be discerned from our genetic 
association findings. None of the GWS SNPs are within 42.1 kb of the KANSL1 start site or 16.8 
kb of the LRRC37A start site, suggesting that the functional variant is not within the promoter 
region of either gene. KANSL1 is a widely expressed gene encoding a member of the nonspecific 
lethal (NSL) complex. The KANSL1 protein is an evolutionarily conserved regulator of the 
chromatin modifier KAT8, which influences gene expression through histone H4 lysine 16 
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(H4K16) acetylation.
9
 Notably, mutations in KANSL1 cause the 17q21.31 microdeletion 
syndrome which is associated with a wide range of abnormalities including intellectual disability 
and developmental delay, and is therefore thought to be involved in neuronal development.
10,11
 
LRRC37A encodes a member of the leucine-rich repeat containing 37 family. Leucine-rich 
repeats (LRRs) are protein-ligand interaction motifs found in a large number of proteins with 
different structure, localization, and function.
12
 LRR motifs are important for intermolecular or 
intercellular interactions with exogenous factors in the immune system and/or with different cell 
types in the developing nervous system.
12 
However, expression analysis of exon array data in control brain tissue revealed that 
rs113986870, which is in high LD with the top-ranked SNP (rs2732703) in the GWAS, is an 
eQTL for expression of the first translated exon in KANSL1 and the alternatively spliced exon 3 
in MAPT. Previous studies suggest that splicing of MAPT may be a crucial regulatory 
mechanism in the brain and tauopathies in particular,
13
 and that increased expression of exon 3 
protects against neurodegeneration.
14
 Although rs113986870 is apparently not an eQTL for its 
adjacent gene LRRC37A, it was significantly associated with a closely related gene, 
LRRC37A4P, in all three AD-related brain regions. These results suggest that rs113986870 may 
have a potential function as a cis-acting regulatory element for multiple genes in this region. 
Another confounding feature of this region are copy number variations that in part overlap with 
the 5’ end of KANSL1 and possibly influence expression.7,8 Thus, it is possible that the exon 
probes targeting the first translated in KANSL1 may be tagging this duplication. In addition, 
interrogation of a database curating information about DNA features and regulatory regions 
revealed that five of the GWS SNPs, including rs2732703 and rs113986870, may have strong 
regulatory potential. 
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The association peak for AD on chromosome 17q21.31 is located in a well-recognized and 
perplexing genomic region containing a 900 kb inversion.
8
 Previous GWAS identified 
associations of variants within and at the edges of this inversion with Parkinson disease (PD)
15
 
and progressive supranuclear palsy (PSP),
16
 but the most significant associations were not with 
SNPs between KANSL1 and LRRC37A (Supplementary Table S6). Multiple studies have 
identified more than 40 MAPT deletions, missense mutations, and splice site mutations that cause 
frontotemporal dementia (FTD).
17
 Although AD is only nominally associated with common 
variants in MAPT, previously we observed association of a rare MAPT variant (A152T) with 
increased risk for FTD and AD in a large sample,
18
 a finding which was supported by a 
subsequent smaller study.
19
 Ikram et al identified a GWS association peak with a KANSL1 SNP 
approximately 166 kb away from our most significant AD SNP (rs2732703) for a continuous 
measure of intracranial volume in a sample of nearly 10,000 community-dwelling elders 
(Supplementary Table S6).
20
 These two SNPs are moderately correlated (r
2
=0.71) which 
indicates that they may tag the same functional variant.  
Other studies have focused on two divergent extended MAPT haplotypes, H1 and H2, which are 
in near complete LD with status of the inversion and contain independently derived partial 
duplications of KANSL1.
8,16
 The common H1 haplotype is associated with increased risk of 
FTD,
21
 PD,
22
 PSP,
23
 and corticobasal degeneration (CBD),
23 
while H2 is linked to recurrent 
deletion events associated with the 17q21.31 microdeletion syndrome.
10
 Among these non-AD 
forms of dementia, it is possible for FTD to masquerade clinically as AD and thereby cases of 
FTD could be present in our study group; however, any inadvertent inclusion of FTD cases is 
expected to be very small since the minimum age of  dementia onset in our study group was 60 
years and onset of dementia from FTD after age 69 years is relatively rare compared to AD that 
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in most cases occurs after age 69.
24
 Furthermore, a recent review of almost 5000 autopsy brains 
from a subset of cases in the ADGC cohort failed to identify any case of FTD.
25
 Myers et al. 
reported association of AD with H1 and with common MAPT SNPs,
26
 but this association is 
controversial
27
 and did not reach genomewide significance in our study or previous GWAS. 
Another recent study showed that carriers of at least one H2 allele had a 5.4-fold increased risk 
of worsening hallucinations, but this result was marginally significant.
28 
Previously, we observed 
in a subset of the sample studied here that the H2-haplotype tagging rs8070723-G allele was 
associated with reduced risk of AD.
29
 However, this variant is no longer associated after 
conditioning on rs2732703 (Supplementary Table S5). In carriers of H2, the ancestral 
haplotype in both humans and chimpanzees,
30
 increased expression of exon 3 in MAPT has been 
associated with an eQTL located approximately 1,500 bp from rs113986870 which decreases 
aggregation of microtubules.
31,32
 These observations are consistent with our results showing that 
the rs113986870 minor allele is protective for AD and associated with elevated exon3 
expression. 
There is a large body of experimental evidence linking tau protein to AD pathogenesis,
33
 and 
some studies show evidence of association of AD with common MAPT SNPs.
29,34
 However, 
analysis of the MAPT coding sequence did not reveal disease-causing variants for early-onset 
AD 
35
 and other studies examining association of MAPT SNPs with late-onset AD were 
negative.
27,36
 Recently, Allen et al. reported that the rs8070723-G allele was associated with 
reduced MAPT expression in the cerebellum and temporal cortex of AD subjects.
29
 Robust 
genetic associations have also been identified for AD with several genes in cytoskeletal and 
axonal transport pathways including tau or leading to neurofibrillary tangles, most notably BIN1, 
EPHA1, RIN3, CASS4, and FERMT2.
4
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Based on the observation that overexpression of human ApoE4 in transgenic mouse neurons 
results in hyperphosphorylation of tau,
37
 it is possible that associations with AD-related loci in 
the chromosome 17q21.31 region are obscured by the much stronger effect of APOE ε4 on 
MAPT expression or function.
38
 This idea is consistent with lack of GWS association with 
17q21.31 SNPs in the same dataset without stratification by APOE genotype,
4
 and no evidence 
for interaction between APOE and any SNPs in the MAPT-KANSL1-LRRC37A region in the 
current study. Another possible explanation for the significant association of 17q21.31 SNPs 
with AD only among subjects lacking APOE ε4 is genetic heterogeneity suggesting that variation 
at the chromosome 17q21.31 locus is associated with a distinct etiological subtype of AD where 
tau is the primary disease activator.
39
 Finally, the diagnosis of AD for most subjects in this 
dataset was established clinically suggesting the possibility of misdiagnosis or AD accompanied 
by other processes associated with other dementing illnesses. Further studies are needed to 
determine whether this subtype can be distinguished clinically or neuropathologically.   
Our study also showed that the previously established association with the MS4A gene cluster is 
derived almost completely from subjects lacking APOE ε4, suggesting the contribution of the 
MS4A locus to AD may be mechanistically different than AD-related processes that are 
associated with APOE ε4. Members of the MS4A gene family encode membrane proteins, some 
of which have known roles in immune cell function,
40
 however, little is known about the 
function of MS4A6A, MS4A4A or MS4A6E in humans. Karch et al. showed that expression of 
MS4A6A was upregulated in AD brains of AD patients compared to brains of controls, and 
significantly correlated with AD status, AIF1 expression (a marker for microglia which is the 
immune cell of the brain), cognitive dementia rating score, and extent of AD neuropathologic 
change.
41
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The observed statistical interaction of genotypes for TMEM106B with APOE on AD risk in the 
stage 1 GWAS is noteworthy (rs1595014, P=1.6x10
-7
) even though it is not supported by results 
in the comparatively small stage 2 sample. TMEM106B is a glycoprotein predominantly 
localized at the lysosomal membrane where it might interact with intracellular progranulin 
(GRN).
42,43
 TMEM106B variants, particularly the p. T185S (rs3173615) mutation, are risk 
factors for FTD, especially among persons carrying a GRN mutation.
44
 TMEM106B variants are 
also associated with development of cognitive impairment in amyotrophic lateral sclerosis
45
 and 
implicated in the pathologic presentation of AD.
46
 Cruchaga et al observed association of the 
TMEM106B SNP rs1990622 risk allele with younger onset of the FTLD subtype with TAR 
DNA-binding protein inclusions (FTLD-TDP),
47
 a pattern reminiscent of the association of 
APOE ε4 with increased risk and younger onset of AD. The biological underpinning of the 
interaction of TMEM106B with APOE affecting AD risk is unclear. 
Our top findings, including those that are genome-wide significant, should be confirmed in 
independent samples. Functional studies will be needed to understand the relationship between 
APOE and the causative variant(s) in 17q21.31 once they are identified, as well as with other loci 
showing much stronger association with AD in particular APOE genotype strata (e.g., 
MS4A6A/MS4A4A/ MS4A6E) or through interaction with APOE (e.g., TMEM106B). Our study 
provides a firm genetic connection of AD to several other pathologically distinct disorders in 
which dementia is a cardinal or common characteristic.  
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Figure Legends 
Figure 1. Association of AD with SNPs in chromosome 17q21.31 in the combined stage 1 and 
stage 2 samples. (A) Regional Manhattan plot in the APOE ε4+ (upper panel) and the APOE ε4- 
(lower panel) subgroups. SNPs with the lowest P-value are indicated with a purple diamond. 
Computed estimates of linkage disequilibrium (r
2
) of SNPs in this region with the most 
significant SNP are shown as red circles for r
2
 ≥ 0.8, orange circles for 0.6 ≤ r2 < 0.8, green 
circles for 0.4 ≤ r2 < 0.6, light blue circles for 0.2 ≤ r2 < 0.4, and blue circles for r2 < 0.2. 
Unannotated SNPs are shown as grey circles. (B) Forest plot of association results for rs2732703 
in the Stage 1, Stage 2 and total samples among APOE ε4- subjects. 
 
Figure 2. Genotype specific effect of the eQTL rs113986870 on expression of KANSL1.  (A) 
Gene-level expression of KANSL1 transcript t3760137. Transcript-level expression represents the 
average across all KANSL1 exon probe sets.  (B) Expression of exon probe 3760212. Probes 
3760211, 3760212, and 3760213 measure expression of the first translated exon, are present in 
all three transcript variants, and were significantly associated with the eQTL. Expression profiles 
for probes 3760211 and 3760213 showed similar to those for probe 3760212 (Table 3). The 
distance from 3760212 to rs113986870 is 85,431 base pairs. Log2 scale of expression (Y-axis) is 
shown for 10 regions of cognitively normal human brains (X-axis) ordered by mean expression 
level. Rs113986870 genotype counts: AA=0, AG=56, and GG=76. Rs113986870 allele 
frequencies are 0.21 (A) and 0.79 (G). CRBL = cerebellum, FCTX = frontal cortex, HIPP = 
hippocampus, MEDU = medulla (specifically inferior olivary nucleus), OCTX = occipital cortex 
(specifically primary visual cortex), PUTM = putamen, SNIG = substantia nigra (SNIG), THAL 
= thalamus, TCTX = temporal cortex), WHMT = intralobular white matter.  
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Table 1.  Association results (P<10
-6
) in novel AD loci among APOE ε4- subjects in the combined stage 1 and stage 2 samples.  
 
SNP CH Region or Closest Gene MA MAF 
Stage 1  Stage 2  Stages 1 + 2 
OR (95% CI) P  OR (95% CI) P  OR (95% CI) P 
rs16847609 3 SOX14/CLDN18 A 0.09 1.21 (1.12-1.29) 2.3x10
-7
  1.09 (0.87-1.37) 0.47  1.19 (1.11-1.28) 5.3x10
-7
 
rs382216 5 CDC42SE2-ACSL6 T 0.36 0.88 (0.83-0.93) 6
.5
x10
-6
  0.78 (0.67-0.91) 0.002  0.87 (0.82-0.92) 2.0x10
-7
 
rs11168036 5 PFDN1/HBEGF T 0.50 1.14 (1.09-1.19) 9.3x10
-9
  0.97 (0.85-1.11) 0.64  1.12 (1.07-1.17) 3.2x10
-7
 
rs2732703 17 KANSL1/LRRC37A G 0.13 0.73 (0.65-0.83) 6.4x10
-7
  0.71 (0.58-0.88) 0.001  0.73 (0.65-0.81) 5.8x10
-9
 
rs71380849 17 CDR2L A 0.06 1.45 (1.24-1.70) 3.8x10
-6
  1.59 (1.01-2.50) 0.04  1.47 (1.26-1.71) 9.1x10
-7
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Table 2.  Results (P<10
-6
) in previously known AD loci showing different pattern of association among APOE ε4+ and ε4- subjects in 
the combined datasets. 
 
 
SNP CH Region or Closest Gene MA MAF 
APOE ε4(+)  APOE ε4(-) 
OR (95% CI) P  OR (95% CI) P 
rs679515 1 CR1 T 0.21 1.22 (1.14 - 1.30) 3.6x10
-9
  1.13 (1.07 - 1.19) 1.6x10
-5
 
rs4663105 2 BIN1 C 0.43 1.19 (1.12 - 1.25) 2.5x10
-9
  1.19 (1.13 - 1.24) 1.8x10
-12
 
rs9331896 8 CLU C 0.38 0.84 (0.80 - 0.89) 2.8x10
-9
  0.90 (0.86 - 0.94) 9.6x10
-6
 
rs1582763 11 MS4 region A 0.37 0.92 (0.87 - 0.97) 0.003  0.87 (0.83 - 0.91) 2.2x10
-9
 
 
CH = chromosome; MA = minor allele; MAF = minor allele frequency. 
  
Page 36 of 38 
 
Table 3.  Exon probes covering the region between 43.5 and 45.0 Mb on chromosome 17 that reveal significant rs113986870 allelic 
expression differences averaged over of 10 brain areas  
 
Gene ExprID Start End AVGALL FCTX HIPP TCTX 
LRRC37A4P 3759896 43583231 43583802 1.4x10
-15
 6.4x10
-4
 4.0x10
-6
 2.4x10
-5
 
LRRC37A4P 3759898 43584264 43584884 1.7x10
-20
 8.0x10
-11
 5.3x10
-10
 3.6x10
-9
 
C17orf69 3723594 43716765 43716853 3.3x10
-13
 2.0x10
-5
 1.6x10
-7
 8.3x10
-5
 
C17orf69 3723604 43723359 43723556 4.9x10
-10
 0.004 9.8x10
-4
 1.3x10
-5
 
MAPT 3723712 44051752 44051833 3.6x10
-14
 9.2x10
-6
 7.6x10
-4
 2.6x10
-6
 
KANSL1 3760158 44117069 44117161 9.8x10
-14
 2.8x10
-5
 0.008 6.2x10
-5
 
KANSL1 3760211 44247654 44247852 4.0x10
-23
 8.0x10
-13
 3.0x10
-17
 1.6x10
-15
 
KANSL1 3760212 44248224 44248977 1.4x10
-24
 2.6x10
-18
 7.8x10
-20
 2.5x10
-21
 
KANSL1 3760213 44249529 44249592 7.7x10
-16
 3.0x10
-11
 1.1x10
-13
 1.2x10
-11
 
KANSL1 3760219 44270189 44270252 4.3x10
-13
 1.3x10
-9
 1.3x10
-8
 1.3x10
-11
 
 
Map position is based on 1000 Genomes database release GRCh37/hg19 assembly, February 2009. Significance threshold after 
multiple testing determined as 0.05/292,000 exon probes = 1.7x10
-7
; ExprID: exon-specific probeset ID. AVEALL: average 
expression levels across 10 regions including cerebellum (CRBL), frontal cortex (FCTX), hippocampus (HIPP), medulla (specifically 
inferior olivary nucleus, MEDU), occipital cortex (specifically primary visual cortex, OCTX), putamen (PUTM), substantia nigra 
(SNIG), thalamus (THAL), temporal cortex (TCTX), and intralobular white matter (WHMT). 
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Figure 1.  
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Figure 2 
 
